Understanding liver cancer care patterns and outcomes
Part of Cancer, Digestive system clinical trials.
This study reviews medical records of people diagnosed with hepatocellular carcinoma (liver cancer) between 2015 and 2023 to better understand how the disease progresses and how different treatments work. Your information helps researchers learn what care approaches work best for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with hepatocellular carcinoma (liver cancer) confirmed by imaging or biopsy between January 2015 and December 2023
- At least 6 months of medical records available after your diagnosis (or all records until you passed away)
- Age 18 or older at the time of diagnosis
- Complete medical records including cause of cancer, lab results, imaging scans, and treatment information
- No other cancer diagnosis before or at the time of your liver cancer diagnosis
- Not currently enrolled in another clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to improve how patients with liver cancer (hepatocellular carcinoma) get the support and information they need. Researchers will interview patients, caregivers, and healthcare providers to find better ways to navigate care.
This study follows people with hepatocellular carcinoma (HCC), a type of liver cancer, to learn how it changes over time. It may help improve understanding of which patients benefit from different care approaches.
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
This study looks at how well doctors can detect small, early liver cancer and then follow how it changes over time. It may help your care team choose the best next steps based on earlier, clearer detection.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This study looks at blood and tissue samples from people with liver cancer to find markers that can predict how well treatment works and whether the cancer might come back. It may help doctors personalize treatment and follow-up care.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.